Cytotoxic T-lymphocyte-associate antigen 4

From Libre Pathology
(Redirected from Ipilimumab)
Jump to navigation Jump to search

Cytotoxic T-lymphocyte-associate antigen 4, abbreviated CTLA-4, is a receptor on the T cell that down regulates immune function.

Antibodies directed at CTLA-4 are used to treat melanoma.

Drugs

  • Ipilimumab.
  • Tremelimumab.

Background

Cytotoxic T cell activation is driven by three sets of receptors:[1]

Pairings Dentritic cell T cell
Antigen presenting MHC TCR
Activation signal B7 CD28
Inhibitory signal B7 CTLA-4

See also

References

  1. Ribas, A. (Jun 2012). "Tumor immunotherapy directed at PD-1.". N Engl J Med 366 (26): 2517-9. doi:10.1056/NEJMe1205943. PMID 22658126.